Nootropics Index - Save on smarter supplements
Nootropics>Botanical & herbal supplements>Boswellia Serrata
Botanical & herbal supplements

Boswellia Serrata

Boswellia serrata gum resin extract

Boswellia serrata is the botanical source of Indian frankincense gum resin extract. Its best human evidence is for joint comfort and mobility measures in knee osteoarthritis studies, not for memory, focus or mental energy. NCCIH notes that oral boswellia may help inflammation and pain associated with osteoarthritis, but also says larger, higher-quality studies are needed and that there is not enough high-quality evidence to determine usefulness for any health condition. Buyers should compare extract type, boswellic-acid or AKBA standardization, and studied dose context instead of classifying boswellia as a nootropic.

Inflammation PathwaysStandardized ExtractFull Spectrum ExtractTraditional UseAyurvedaClinical ResearchLimited Human Evidence
Updated August 2026/5 min read/7 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What boswellia is

2

Boswellia serrata is a tree whose gum resin is used to make Indian frankincense extract. Supplement products usually focus on boswellic acids or AKBA-enriched extracts, not the essential oil used for aromatherapy.

Not a nootropic evidence story2
Boswellia appears in supplement catalogs and may be compared by nootropics buyers, but the human evidence base is joint-centered. There is no credible basis to present it as a memory, focus or mental-energy supplement.

Joint evidence is the main human signal

4

The 2020 meta-analysis included seven randomized osteoarthritis trials with 545 participants and reported better pain, stiffness and function scores for Boswellia or Boswellia extract versus control. NCCIH is more cautious overall, emphasizing that most studies are small or low quality and that better trials are needed.

Branded extracts do not generalize to every product

6

The 5-Loxin trial used an AKBA-enriched extract at 100 or 250 mg/day for 90 days in knee osteoarthritis participants. That result does not automatically transfer to unstandardized powders, essential oils, low-AKBA extracts or products that do not disclose their extract chemistry.

02

Names, aliases and forms

Latin NameBoswellia serrata
Common NamesBoswellia; Indian frankincense
Traditional NameOlibanum
Extract NameBoswellia serrata extract (BSE)
Active ConstituentsBoswellic acids; AKBA
03

Potential effects and evidence map

Boswellia serrata has human research, but the evidence is mostly joint-focused. NCCIH summarizes the overall evidence as limited by small and low-quality studies, while noting that oral boswellia has shown signals for osteoarthritis-related inflammation and pain. A 2020 systematic review and meta-analysis included seven randomized trials with 545 osteoarthritis participants and reported better pain, stiffness and function scores versus control, but the authors still relied on a small trial base. Earlier trials of Boswellia serrata extract and 5-Loxin used knee osteoarthritis populations and cannot be reframed as cognitive-performance evidence.

Effect domainMagnitudeGrade
Memory / learning2
UnknownConfidence: High

No human evidence supports Boswellia serrata for memory or learning.

Note Joint/OA studies should not be reframed as cognition evidence.

0/5
E
Focus / attention2
UnknownConfidence: High

No human evidence supports Boswellia serrata for focus or attention.

Note Not a productivity supplement based on current human evidence.

0/5
E
Mental energy / wakefulness2
UnknownConfidence: High

No reliable evidence supports Boswellia serrata for mental energy or wakefulness.

Note Avoid energizing or stimulant-style copy.

0/5
E
Mood / wellbeing2
UnknownConfidence: Medium

No meaningful human mood evidence was identified.

Note Current clinical evidence is not mood-centered.

0/5
E
Cellular / long-term brain support3
UnknownConfidence: Medium

Human brain-support evidence is lacking.

Note MSK mentions animal-model cognitive findings, but those are not human nootropic evidence.

0/5
E
04

Typical dosages and timing

Typical
100 to 1000 mg/day
Not a recommendation
Extract-specific study doses2Up to 1000 mg/day

Human studies use product-specific extracts, so dose comparisons should start with extract type and standardization. NCCIH notes Boswellia serrata extract doses up to 1000 mg/day have been used in trials lasting up to 6 months, while the 5-Loxin knee trial used 100 or 250 mg/day for 90 days.

05

Timing & effect horizon

Effect horizonUnknown
Unknown
Do not convert study length into a cycle4

The 2020 review discussed at least 4 weeks of use in osteoarthritis studies, and NCCIH summarizes trial safety up to 6 months for some extracts. That is study-duration context, not a recommended cycle and not an effect-duration claim.

06

Safety, side effects and risk profile

Generally low risk at studied oral doses2
NCCIH describes oral boswellia as likely safe and notes Boswellia serrata extract up to 1000 mg/day has been used safely in several clinical trials lasting up to 6 months. The evidence is still short-term and product-specific.
Pregnancy, nursing and blood-thinner caution2
NCCIH says food amounts are likely safe during pregnancy or breastfeeding, but little is known about medicinal oral amounts. MSK also flags blood thinners such as warfarin because bleeding risk may be higher.
Do not substitute for asthma or cancer care2
NCCIH notes only small or limited human studies in asthma, cancer-care and brain-edema contexts. Boswellia should not be used to replace clinician-directed care in those situations.
Evidence uncertainty2
Confidence: High

The human evidence is joint-focused, formulation-dependent and limited by small or lower-quality studies.

Note NCCIH cautions that larger, higher-quality studies are needed.

2/5
C
GI discomfort5
Confidence: Medium

The 2003 knee trial reported minor gastrointestinal adverse events, and NCCIH still frames oral use as likely safe at studied doses.

Note Mild GI tolerability is the main trial-level concern identified here.

2/5
C
Pregnancy / lactation caution2
Confidence: Medium

NCCIH says food amounts are likely safe, but data for medicinal oral amounts during pregnancy or breastfeeding are limited.

Note Use a clear vulnerable-group caution without overstating known harm.

3/5
D
main practical issues3

The 2003 knee trial reported minor gastrointestinal adverse events, and MSK lists allergic skin reactions as a possible side effect. Stop casual use and get appropriate review if a rash, swelling, severe stomach upset or unusual bleeding occurs.

07

Practical buying and quality notes

  • Compare the exact species, resin/extract form, boswellic-acid percentage, AKBA content, dose per serving, serving count and third-party purity testing. A frankincense essential oil, a raw resin, a generic powder and an AKBA-enriched oral extract are not interchangeable.7
08

FAQ

Is Boswellia serrata a nootropic?

2

No. Current human evidence is centered on joint outcomes, especially knee osteoarthritis studies. Memory, focus and mental-energy claims are not supported.

What dose of Boswellia serrata is commonly studied?

2

Study doses depend on the extract. NCCIH describes Boswellia serrata extract amounts up to 1000 mg/day in trials, while one AKBA-enriched knee-osteoarthritis study used 100 or 250 mg/day; those examples are not interchangeable product recommendations.

How long is Boswellia serrata usually studied?

2

Many osteoarthritis studies run for 4-12 weeks, and NCCIH notes trial safety data up to 6 months for some oral extracts. That is study-duration context, not a recommended cycle.

09

References

  1. NCBI Taxonomy Browser. Boswellia serrata, taxonomy ID 613112.
  2. National Center for Complementary and Integrative Health. Boswellia: Usefulness and Safety.
  3. Memorial Sloan Kettering Cancer Center. Boswellia.
  4. Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. 2020.
  5. Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double blind placebo controlled trial. Phytomedicine. 2003.
  6. Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Research & Therapy. 2008.
  7. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clinical Pharmacokinetics. 2011.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.